89bio Inc (ETNB)
8.70
-0.01
(-0.11%)
USD |
NASDAQ |
May 13, 16:00
8.70
0.00 (0.00%)
Pre-Market: 20:00
89bio Research and Development Expense (Quarterly): 47.43M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 47.43M |
December 31, 2023 | 33.59M |
September 30, 2023 | 31.42M |
June 30, 2023 | 34.92M |
March 31, 2023 | 22.31M |
December 31, 2022 | 19.06M |
September 30, 2022 | 22.20M |
June 30, 2022 | 19.69M |
March 31, 2022 | 19.85M |
December 31, 2021 | 20.98M |
September 30, 2021 | 23.59M |
June 30, 2021 | 15.63M |
Date | Value |
---|---|
March 31, 2021 | 10.13M |
December 31, 2020 | 8.77M |
September 30, 2020 | 11.21M |
June 30, 2020 | 8.443M |
March 31, 2020 | 7.778M |
December 31, 2019 | 7.192M |
September 30, 2019 | 6.68M |
June 30, 2019 | 3.165M |
March 31, 2019 | 4.309M |
December 31, 2018 | 3.692M |
September 30, 2018 | 3.289M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
3.165M
Minimum
Jun 2019
47.43M
Maximum
Mar 2024
18.70M
Average
19.38M
Median
Research and Development Expense (Quarterly) Benchmarks
Akero Therapeutics Inc | 50.65M |
Madrigal Pharmaceuticals Inc | 71.24M |
Viking Therapeutics Inc | 24.10M |
Galectin Therapeutics Inc | 8.228M |
Terns Pharmaceuticals Inc | 17.46M |